- 全部删除
- 您的购物车当前为空
IL-1RA Protein, Human, Recombinant (HEK293) is expressed in HEK293 Cells. The accession number is P18510.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 μg | ¥ 539 | 5日内发货 | |
50 μg | ¥ 1,080 | 5日内发货 | |
1 mg | ¥ 10,800 | 5日内发货 |
生物活性 | ED 50 < 0.1 μg /ml, measured in a neutralization assay using D10S cells in the presence of 50.0 pg/ml Human IL-1a. |
产品描述 | IL-1RA Protein, Human, Recombinant (HEK293) is expressed in HEK293 Cells. The accession number is P18510. |
种属 | Human |
表达系统 | HEK293 Cells |
标签 | Tag Free |
蛋白编号 | P18510 |
别名 | IRAP,IL-1RN,IL1RA,ICIL-1RA |
蛋白构建 | Arg26-Glu177 |
蛋白纯度 | > 95% as determined by SDS-PAGE; > 95% as determined by HPLC |
分子量 | 18~23 kDa (Reducing conditions) |
内毒素 | < 0.2 EU/μg of protein as determined by the LAL method. |
缓冲液 | Lyophilized from a 0.2 μm filtered solution in PBS. |
复溶方法 | Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
存储 | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
研究背景 | IL-1 Receptor Antagonist, also known as IL-1RA, ICIL-1RA, IRAP and IL-1RN, is a member of the interleukin 1 cytokine family. It is expressed by monocytes, neutrophils, macrophages, epithelial cells and fibroblasts. IL-1RA inhibits the activity of both IL-1alpha and IL-1beta, and modulates a variety of IL-1 related immune and inflammatory responses. It inhibits the activity of IL-1 by binding to the receptor IL-1R1 and preventing its association with the coreceptor IL-1RAP for signaling. Clinical studies are being conducted to investigate the use of IL-1RA in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia. |